Glaxo holds its breath
A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
Mitsubishi's Medicago heads for the Covid-19 booster queue
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Bavarian Nordic goes it alone, for now
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
RSVVW 2021 – Pfizer gets maternal
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
